U.K. cost watchdog rejects Roche, GSK cancer meds

The U.K. hasn't been kind to high-tech cancer drugs this week: The cost-effectiveness watchdog NICE rejected Roche's Herceptin and GlaxoSmithKline's Tykerb for use in breast cancer patients in combination with hormone-blocking drugs; and Roche's Avastin got stiff-armed as a treatment for colorectal cancer that has spread. Article | Report

Suggested Articles

AstraZeneca has signed a $750 million deal to produce up to 300 million doses of Oxford University's COVID-19 vaccine by year's end.

Moderna is entering an important time, its CEO says. And the company is doing so with a new finance chief from Big Biotech.

A new NEJM study found taking hydroxychloroquine after COVID-19 exposure doesn't reduce the risk of an infection. But questions remain.